REQUEST A CONSULTATION

Ready to contact us for a consultation about your condition and our medical services? The staff of our Global Patient Services is ready to help. Please select the appropriate button to get started.
search-icon
News

Benefits of Combination Immunotherapy for Metastatic Melanoma Patients

Immunotherapy combination can prolong patient lifepsan
According to a recent Sheba study, a combined immunotherapy regimen of Yervoy (Ipilimumab) and Opdivo (Nivolumab) can significantly increase long-term survival rates.

Cancer immunotherapy refers to a variety of treatments that utilize the body’s own immune system to fight the disease. These treatments work in several ways – either by boosting your immune system in general or stimulating your immune system to recognize and attack specific cancer cells. Over the past decade, immunotherapy has become an essential part of treating certain types of cancer.

A long-term study conducted at Sheba Medical Center compared three different metastatic melanoma immunotherapy regimens to determine which is most effective. Participants were divided into groups, the first of which were administered Yervoy (Ipilimumab), the second Opdivo (Nivolumab), and the third a combination of the two.

The study observed metastatic melanoma patients for 6.5 years, and results indicated that patients treated with the combined immunotherapy regimen lived longer: 50% of participants who received the combined regimen survived for six years compared to three among patients treated exclusively with either drug.

While results suggest that for many the most effective treatment is a combined immunotherapy regimen, it is also noted that this is most applicable to older patients (aged 80 or more) or those with milder cases of the malignancy, i.e., a single immunotherapy drug can be quite effective for many other patients.

Related

Ayelet’s Miracle: The First Woman to Conceive Four Children Following Ovarian Tissue Cryopreservation

At 21, Ayelet Rozenberg was diagnosed with Hodgkin’s lymphoma. Facing aggressive therapies necessary to save her life, Ayelet feared she would never be able to…
Read More
bowel disease
News Sep 07.

Sheba Partners with Biomica to Advance Inflammatory Bowel Disease Care

As part of the new collaboration, Sheba and Biomica will engage in joint microbiome clinical research to develop better treatments for inflammatory bowel disease (IBD)…
Read More
Hemophilia research
News Sep 05.

New Sheba Study Indicates: Novel Treatment Sharply Reduces Bleed Rates Among Hemophilia Patients

Results indicate that a monthly treatment with Fitusiran significantly reduces bleed rates among both hemophilia A and B patients.
Read More